{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"5.1","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"}],"units":"Participants"}],"description":"Infusion reaction was defined as any relevant sign or symptom occurring during or after elotuzumab infusion and considered by the investigator as an infusion reaction. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Potentially Life-threatening or disabling, Gr 5=Death.","dispersionType":"95% Confidence Interval","groups":[{"description":"E-Ld refers to the combination of Elotuzumab with Lenalidomide/Dexamethasone.","id":"OG000","title":"E-Ld"}],"paramType":"NUMBER","populationDescription":"All Treated Participants","reportingStatus":"POSTED","timeFrame":"From Day 1 to End of cycle 2 treatment (approximately 56 days)","title":"Number of Participants With Grade 3 or Grade 4 (G3/4) Infusion Reactions by the End of Treatment Cycle 2","type":"PRIMARY","unitOfMeasure":"Participants"}